e-Drug3D

1068

IVERMECTIN


INN
IVERMECTIN

cas 70288-86-7
CLASS

ANTIPARASITIC
ANTHELMINTICS
ANTINEMATODAL AGENTS
ANTIPROTOZOAL AGENTS
INCREASE THE PERMEABILITY OF THE CELL MEMBRANE TO CHLORIDE IONS WITH HYPERPOLARIZATION BUT DOES NOT READILY CROSS THE BLOOD-BRAIN BARRIER IN HUMANS
BINDS GLYCINE RECEPTOR

ROUTE (list)

ORAL TOPICAL

ATC code

D11AX22
P02CF01

PK parameters

Tmax 4 HOUR
PPB 99 PERCENT
t1/2 18 HOUR

Solubility

INSOLUBLE IN WATER


Target

TARGET GLYCINE RECEPTOR (GLYR)
GLUTAMATE-GATED CHLORIDE CHANNEL
GABA RECEPTOR
NS3 HELICASE (PMID22535622)

PDB
3JAF (DANIO RERIO ALPHA-1 GLYCINE RECEPTOR BY CRYO-EM)

Ligand code = IVM (link to the list of PDB complexes)

Download experimental 3D coordinates of IVM with added hydrogens

DrugCentral

Glutamate-gated chloride channel UNIPROT P91730

Glutamate-gated chloride channel UNIPROT Q25634 GluClX

Download SDF file IVERMECTIN

Formula:
C48H74O14

Calculated chemical properties:

MW 875.07
NB_atoms 62
XLogP 5.60
PSA 173.266
NB_HD 3
NB_HA 14
fsp3 0.81
Lipinski(0=no;1=yes) 0

FDA
NDA 050742 (label) INN (IVERMECTIN) STROMECTOL (MERCK SHARP DOHME) APPROVAL= AP YEAR= 1996
NDA 202736 (label) INN (IVERMECTIN) SKLICE (ARBOR PHARMS LLC) APPROVAL= AP YEAR= 2012
NDA 204154 (label) INN (IVERMECTIN) IVERMECTIN (EDENBRIDGE PHARMS) APPROVAL= AP YEAR= 2014
NDA 206255 (label) INN (IVERMECTIN) SOOLANTRA (GALDERMA LABS LP) APPROVAL= AP YEAR= 2014
NDA 210019 (pdf not found) INN (IVERMECTIN) IVERMECTIN (TEVA PHARMS USA) APPROVAL= AP YEAR= 2019
NDA 210225 (pdf not found) INN (IVERMECTIN) IVERMECTIN (PADAGIS ISRAEL) APPROVAL= AP YEAR= 2020
NDA 210720 (pdf not found) INN (IVERMECTIN) IVERMECTIN (TARO) APPROVAL= AP YEAR= 2020
NDA 212485 (pdf not found) INN (IVERMECTIN) IVERMECTIN (TEVA PHARMS USA) APPROVAL= AP YEAR= 2022 DISCONTINUED
NDA 215210 (pdf not found) INN (IVERMECTIN) IVERMECTIN (ZYDUS LIFESCIENCES) APPROVAL= AP YEAR= 2022
NDA 218324 (pdf not found) INN (IVERMECTIN) IVERMECTIN (SENORES PHARMS) APPROVAL= AP YEAR= 2024
NDA 215922 (pdf not found) INN (IVERMECTIN) IVERMECTIN (RUBICON RESEARCH) APPROVAL= AP YEAR= 2025

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL